1. Introduction
Cardiac remodeling encompasses changes at the molecular, cellular and transcriptional level following pathologic insult to the heart and is characterized by gradual functional and structural decline [
1]. Excessive β-adrenergic stimulation and tachycardia are potent triggers of cardiac remodeling [
2,
3,
4,
5], and while many aspects of their cellular effects are well understood, others remain elusive. Initially, elevated β-adrenergic stimulation signals the heart to use its chronotropic and inotropic reserve, thereby stabilizing blood pressure and cardiac output and allowing patients to remain asymptomatic for a limited post-insult time [
2]. If prolonged, however, it leads to progressive decline in contractile function, constituting a vicious cycle that eventually causes organ failure.
β-adrenergic stimulation and tachycardia are well documented to increase intracellular calcium (Ca
2+) cycling in cardiomyocytes [
4,
6]. Although this is critical for enhancing myofilament contraction and matching the increased energy demands by stimulating mitochondrial ATP production, little is known about the effects of β-adrenergic stimulation-mediated increase in intracellular Ca
2+ on transcriptional regulation in the process of excitation–transcription coupling [
7,
8]. Excitation–transcription coupling is a very early key feature of cardiac remodeling in cardiomyocytes [
4,
9,
10], and it conveys the activation of ion-handling molecules at the sarcolemma into transcriptional reprograming with subsequent structural and functional consequences [
5,
11,
12]. Several Ca
2+-handling molecules have been implicated in excitation–transcription coupling and the subsequent development of hypertrophy. In our previous work, we systematically studied the contribution of sodium–calcium exchanger (NCX), sodium–proton exchanger (NHE), sodium channel (Nav 1.5), sodium potassium pump (Na
+/K
+ ATPase), L-type calcium channel (LTCC), transient receptor potential channel (TRP), calcium/calmodulin-dependent protein kinase II (CaMKII) and calcineurin to hypertrophic remodeling due to tachycardia [
5]. We demonstrated that NCX most prominently contributed to tachycardia-mediated alterations in Ca
2+-mediated transcriptional regulation and that this effect was linked to CaMKII activation via phosphorylation that occurred downstream of NCX. Despite the correlation of tachycardia with increased β-adrenergic tone and β-blocker therapy being a mainstay of the pharmacological treatment of heart failure [
2], the contribution of β-adrenergic signaling to the processes of excitation–transcription coupling under the conditions of increased workload and tachycardia has so far not been comprehensively documented.
Here, we aimed to study the individual and synergistic potency of β-adrenergic stimulation and tachycardia to modulate pathological gene expression profiles, as well as the efficacy of β-blocker treatment in preventing these alterations. Using neonatal rat ventricular cardiomyocytes (NRVCMs), we showed that β-adrenergic signaling can—via limiting NCX upregulation and potentiating CaMKII activity specifically on the sarcoplasmic reticulum and the nuclear envelope—prevent the upregulation of interleukin-6 receptor (IL6R) under increased workload. Furthermore, we showed that blunted β-adrenergic signaling is associated with NCX upregulation and enhanced IL6R signaling in hypertensive Dahl salt-sensitive rats. We propose a previously unrecognized protective role of β-adrenergic signaling in preventing IL6R upregulation and NCX dysregulation under increased workload, molecular mechanisms that are severely disrupted in cardiac pathologies. A better understanding of these processes may contribute to refinement of patient care, with special regard to the use of β-blockers.
2. Materials and Methods
2.1. Ethical Consideration
All procedures involving animals conformed to the EU Directive 2010/63/EU and were approved by the institutional ethical committee and the Austrian Federal Ministry of Education, Science and Research (Vienna, Austria; BMBWF-66.010/0147-V/3b/2018).
2.2. Isolation and Culture of Neonatal Rat Ventricular Cardiomyocytes
Isolation and culture of
neonatal rat ventricular cardiomyocytes (NRVCMs) were performed as previously described [
5,
9], with minor adaptations. Briefly, female rats with timed pregnancy were purchased from Charles River Laboratories (Sulzfeld, Germany), and hearts were excised from 1-day-old Wistar pups (15-17 pups per isolation) following cervical dislocation. Hearts were then minced and digested using a liberase-based approach (digestion solution: 1X HBSS, 0.08% Liberase
TM Research Grade (Merck, Darmstadt, Germany), 0.1% Trypsin Gibco
TM (Thermo Fisher Scientific, Waltham, MA, USA), 0.2% DNAse I (Merck, Darmstadt, Germany), 10 µM CaCl
2 and 20 mM HEPES; pH 7.3) at 37 °C and 0% CO
2. After 10 min of digestion, the supernatant was discarded, and fresh digestion solution was added to the remaining pieces four times for 15 min. The supernatant was collected and digestion was stopped by adding 10% horse serum Gibco
TM (Thermo Fisher Scientific, Waltham, MA, USA). Isolated cells were centrifuged in a Heraeus multifuge (Thermo Fisher Scientific, Waltham, MA, USA) for 8 min at 350×
g, and pellets were resuspended in culture medium (DMEM/F12, GlutaMAX
TM containing 10% FBS and 1% Penicillin/Streptomycin) and finally pooled for further processing.
After filtering through a 100 µm nylon mesh filter, cells were pre-plated in cell culture flasks (90 min at 37 °C and 5% CO2) to remove potential non-myocytes. NRVCMs were plated at a density of 106 cells/ml on gelatin-plated 35 mm glass-bottom dishes for immunocytochemistry (Greiner Bio-One, Kremsmünster, Austria) or plastic-bottom dishes for qPCR (Greiner Bio-One, Kremsmünster, Austria). One day post-isolation, media was exchanged for serum-free media (DMEM/F12, GlutaMAXTM containing 20% Medium M199/GlutaMAXTM and Penicillin/Streptomycin). NRVCMs were ultimately cultured for 3 days prior to induction of acute experimental conditions.
NRVCMs were electrically stimulated with carbon electrodes (C-pace EP, IonOptix, Westwood, KS, USA) for 3 h at 37 °C and 5% CO2 at either 1 Hz (CTL) or 8 Hz (Tachycardia, TC) in control media or media containing 10 µM isoprenaline (ISO), 10 µM ISO after 1 h preincubation with 1 µM propranolol (β-blocker, ISO + BB) or 1 µM ORM-10962 (NCX inhibitor, ORM). Cell contractility was monitored using a conventional light microscope.
2.3. Rat Model of Hypertension, In Vivo Characterization Methods and Gravimetry
Male Dahl Salt-Sensitive (DSS) rats were purchased from Charles River Laboratory (Boston, MA, USA) at 4–5 weeks of age. Starting at 7 weeks of age, rats were fed either a high-salt diet (HSD, 8% NaCl; Research Diets; D05032408Y) to induce hypertension or a low-salt diet (LSD, 0.3% NaCl; Research Diets; D10001R) as a control (see
Figure S1A in the Supplementary Materials for a schematic overview of the feeding and experimental protocol). Rats remained on their respective diets for 10 weeks to study hypertension-induced cardiac remodeling.
Blood pressure (BP) measurements were carried out biweekly using the CODA® tail cuff system (Kent Scientific Corporation, Torrington, CT, USA). Recordings were performed in steady-state conditions, and values from three consecutive measurements were averaged.
Cardiac function was assessed via transthoracic echocardiography [
10] using Vevo 3100 (VisualSonics, Toronto, ON, Canada) with rats under light anesthesia (Isoflurane, 1-1.5% and 1.5–2 l/min oxygen flow). For determination of ejection fraction (EF) and left ventricular (LV) mass in M-mode, images were acquired in the parasternal long axis. To assess diastolic function, the ratio of peak early Doppler transmitral flow velocity (E) to myocardial-tissue Doppler velocity (e′), images using pulsed-wave Doppler and tissue Doppler mode were acquired in a modified parasternal long axis and parasternal short axis, respectively.
After euthanasia by cervical dislocation of heavily anesthetized rats, organs were collected and gravimetric measurements of body weight (BW) and heart weight (HW) were noted.
2.4. Isolation of Adult Cardiomyocytes
For isolation of ventricular cardiomyocytes from adult Dahl salt-sensitive rats, a liberase-based Langendorff perfusion protocol as previously described for mice [
4,
6] was optimized and modified.
In detail, the thoracic cavity of heparinized animals (500IE) was opened after sacrifice, and the heart was rapidly excised and submerged in ice-cold perfusion buffer (PB, in mM: 135 NaCl, 4.7 KCl, 0.6 KH
2PO
4, 0.6 HNa
2PO
4dibasic, 1.2 MgSO
4*7H
2O, 10 HEPES, 30 Taurin, 10 BDM, 10 Glucose) supplemented with 1 mM CaCl
2. The aorta was cannulated for retrograde perfusion and the coronaries flushed of remaining blood. Following 1.5 min of perfusion with temperature-controlled Ca
2+-free solution (PB) at 37 °C, hearts were digested using 6 mg/ml Liberase
TM Research Grade (Merck, Darmstadt, Germany) and 0.014% Trypsin Gibco
TM (Thermo Fisher Scientific, Waltham, MA, USA) in PB with 12.5 µM CaCl
2 for 9–12 min (depending on visible signs of digestion). Digestion was stopped by submerging ventricles in a bovine calf serum (BCS)-containing stop solution (PB with 12.5 µM CaCl
2 and 10% BCS), and the tissue was carefully dissociated using a cut and blunted Pasteur pipette and sieved through a 300 µm mesh. Cardiomyocytes were allowed to settle by gravity before exposure to a series of increasing [Ca
2+] (PB with 5.0% BCS, and CaCl
2 in 5 steps), reaching a maximum of 1.5 mM CaCl
2. For subsequent immunocytochemistry [
10], cells were plated on laminin-coated glass-bottom dishes (prepared the night before) and allowed to attach for 1 h at room temperature in the final CaCl
2 solution before exposure to Normal Tyrode’s solution (NT, in mM: 140 NaCl, 4 KCl, 1 MgCl
2*6H
2O, 10 HEPES, 1.5 CaCl
2, 5 Glucose) at 37 °C and 5% CO
2 for a subset of cells pacing at 0.2 Hz for 1 h (C-pace EP, IonOptix, Westwood, KS, USA).
2.5. Immunocytochemistry and Confocal Imaging
To fix NRVCMs, cell culture media was rapidly removed, and cells were exposed to 4% PFA/PBS for 10 min. For adult cardiomyocytes, concentrated PFA was added directly to NT, and cells were fixed in a solution ultimately containing 1% PFA for 10 min.
Permeabilization was performed in 0.1% (for NRVCMs) or 0.6% (for adult cardiomyocytes) Triton X-100 in PBS for 10 min at RT, and cells were subsequently washed in PBS. Incubation with primary antibody (anti-NCX1, 1:300, R3F1, Swant, Burgdorf, Switzerland; anti-pCaMKIIT286, 1:500, ab32678, or anti-ADRB1, 1:100, ab3442, both Abcam, Cambridge, UK) in a solution containing 5% BSA, 3% goat serum and 0.01% Triton X-100 in PBS was performed for either 4–5 h at RT or overnight at 4 °C. Cells were then washed twice in 0.01% Triton X-100 in PBS and incubated with secondary fluorescent antibody (anti-rabbit Alexa647, 1:1000, cs4414; anti-mouse Alexa488, 1:500, cs4408, both Cell Signaling Technology, Danvers, MA, USA, or anti-rabbit Alexa647, 1:500, ab150075, Abcam, Cambridge, UK) for 1.5 h at RT and protected from light. Cells were washed twice in 0.01% Triton X-100 and twice in PBS before staining with DAPI (1:200) for 10 min at RT. Finally, cells were washed 3 times in PBS and imaged using a confocal fluorescence microscope (LSM 510 Meta with a Plan Neofluar 40x/1.3 oil-immersion objective, Carl Zeiss, Jena, Germany). Image J software (NIH, Bethesda, MD, USA) was used to measure mean fluorescence intensity in the region of interest. To minimize effects of cohort variability and antibody inter-batch variability, background-subtracted signals were normalized to mean of the corresponding controls. Hypertrophy measures were taken by measuring cell length and width with the measuring tool in Image J.
2.6. Isolation of RNA and Quantitative Real-Time PCR (qPCR) of NRVCMs
Cells were scraped from plastic-bottom dishes and lysed in Qiazol
TM lysis reagent, and total RNA was isolated with the miRNeasy
® Kit (Qiagen, Hilden, Germany). RNA yield and quality were assessed with the NanoDrop
TM 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Subsequent gDNA wipeout and cDNA synthesis using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany) were carried out in a peqStar Thermocycler (VWR, Radnor, PA, USA). cDNA was diluted to a working concentration of 10 ng per reaction volume for qPCR. qPCR was performed using the TaqMan-System (TaqMan
TM Gene Expression Master Mix and TaqMan
TM Assays; Thermo Fisher Scientific, Waltham, MA, USA; primers listed in
Table S1) according to the manufacturer’s instructions, and a Bio-Rad CFX384 Touch Real-Time PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA, USA). GenEx 5.4.4. (MultiD, Gothenburg, Sweden) was used for efficiency correction on all primer sets, followed by relative quantification of gene expression with the 2
−ΔΔCt quantification method. GAPDH served as the housekeeping gene. All procedures were carried out according to the MIQE guidelines [
13].
2.7. Protein Extraction and Immunoblotting of Cardiac Tissue from Adult Dahl Salt-Sensitive Rats
Tissue samples were homogenized utilizing freshly prepared ice-cold homogenization buffer (HP in mM: 137 NaCl, 20 Tris-HCl pH 7.4, 20 NaF, 1 Na-orthovandat, 1 Na-pyrophsophat, 50 β-glycerolphosphat, 10 EDTA pH 8, 1 EGTA pH 7, 1 PMSF; 1% IGEPAL, 10% glycerol, 4 µg/mL each: aprotinin, leupeptin and pepstatin A) by mincing and the use of an electric homogenizer. After collecting the supernatant in two short centrifugation steps at 8000 rpm at 4 °C, the homogenate was centrifuged at full speed for 10 min at 4 °C to collect the protein fraction in the supernatant. Protein concentration was determined by PierceTM BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol, and the absorbance was measured at 562 nm with a SpectraMax® Plus 374 photometer (Avantor, VWR, Radnor, PA, USA).
For immunoblotting, 30 µg of sample underwent electrophoresis using a Bis-Tris/MOPS-based approach and 4–12% gradient gels. Electrophoresis was initiated at 70 V for 10 min and then increased to 120 V for approximately 2.5 h on ice. Protein transfer was carried out for 2 h at 400 mA and 4 °C using ice-cold transfer buffer (in mM: 192 glycine, 25 Tris, 20% Methanol). Total protein content was detected by staining membranes for 3–5 min in Ponceau S and documented using the ChemiDocTM Touch Imaging System (Bio-Rad Laboratories Inc, Hercules, CA, USA). Blocking was performed with 5% milk powder in TBST for 1 h at RT before incubation with primary antibody (anti-NCX1, 1:5000, ab177952, Abcam, Cambridge, UK; anti-Serca2a, 1:5000, A010-20, Badrilla, Leeds, UK and anti-GAPDH, 1:2000, cs5174, Cell Signaling Technologies, Danvers, MA, USA) in 0.5% MP/TBST overnight at 4 °C. Membranes were washed 3 times in TBST before incubation with secondary antibody (anti-rabbit HRP conjugated, 1:5000, NA934V, Cytvia, Malborough, MA, USA) for 1 h at RT and washed again 3 times in TBST.
For detection of chemiluminescence, membranes were incubated with Clarity Western ECL substrate (Bio-Rad Laboratories Inc., Hercules, USA) for 2–3 min and subsequently imaged in signal accumulation mode on the ChemiDocTM Touch Imaging System (Bio-Rad Laboratories Inc., Hercules, CA, USA). Densitometric quantification of bands was performed using ImageLab software (Bio-Rad Laboratories Inc., Hercules, CA, USA) using the “lanes and bands” tool with manual adjustments. Signal intensity of the protein of interest was normalized to corresponding intensity of the housekeeping protein (GAPDH).
2.8. RNA Extraction and Microarrays of Cardiac Tissue from Adult Dahl Salt-Sensitive Rats
RNA from left ventricular tissue was isolated using the microRNeasy
® Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. RNA concentration was determined by NanoDrop
TM 2000 (Thermo Fisher Scientific, Waltham, MA, USA) before samples were shipped to ATLAS Biolabs (Berlin, Germany) for transcriptomic profiling using Affymetrix WT Expression Profiling Microarray Clariom D (Thermo Fisher Scientific, Waltham, MA, USA). For data analysis, CEL files were imported in transcriptome analysis console, Version 4.0 (Applied Biosystems, Waltham, MA, USA), and individual data points were exported. Values presented are log2 transformed mean signal intensities. Relevant transcript IDs and additional information are provided in
Table S2.
2.9. Statistics
Statistical analysis was performed in GraphPad Prism 9 (San Diego, CA, USA). Data were tested for normality of distribution by Shapiro–Wilk test and D’Agostino–Pearson test.
In case of normal distribution and comparison of 2 groups, a t-test was applied. If the normality of distribution was violated, a Mann–Whitney test was conducted. For comparison of 3 groups, normal distribution was always violated; therefore, a Kruskal–Wallis test was conducted. In the case of comparison of trigger-induced changes to baseline levels of the same sample, a one-sample t-test was employed. For statistical analysis of grouped data (body weight and blood pressure curves), a mixed-effect analysis for overall effects and multiple unpaired t-tests for individual time points were employed. After correction for multiple testing where appropriate, a two-tailed p ≤ 0.05 was considered significant. The corresponding statistical tests for each data set are indicated in the figure legends.
4. Discussion
The results of the present study indicate that acute β-adrenergic receptor stimulation prevents overactivation of IL6R-signaling in the heart under physiological stress, thereby preventing transcriptional remodeling and maladaptive response to short-term increases in cardiac workload. Mechanistically, two features of β-adrenergic signaling are associated with this effect: (1) prevention of NCX overexpression and (2) potentiation of CaMKII signaling, specifically on intracellular Ca2+ stores, the sarcoplasmic reticulum and nuclear envelope. In addition, conditions of chronic β-adrenergic signaling depression are characterized by NCX upregulation and are followed by a dramatic increase in IL6R signaling. These data could help the refinement of existing cardioprotective strategies, especially for patients commencing β-blocker therapy and/or those with advanced hypertension.
Cardiomyocytes can directly release
IL6 in response to injury and cardiac stress. The duration of
IL6 production and signaling by cardiomyocytes determines whether this signaling is protective and capable of limiting cellular damage or detrimental, with the latter leading to chronically depressed cardiac function [
18]. In response to injury,
IL6 acutely diminishes cardiomyocyte contractility, activates anti-apoptotic signaling and preserves the viability of the myocardium [
19,
20]. However, both animal and human studies have showed that if
IL6 signaling remains elevated after the immediate need to preserve the insulted tissue has resolved, reduced contractility of the myocardium induces activation of hypertrophic gene signaling, which can eventually lead to heart failure [
21,
22]. For example, IL6-family signaling was shown to decrease the basal contractility of cardiomyocytes and their β-adrenergic responsiveness, ultimately leading to decreased function [
23,
24], as well as induction of gene expression that is essential for the development of pathological hypertrophy via activating CaMKII and STAT3 pathways [
25,
26]. In contrast, inhibition of
IL6 signaling by disrupting IL6/gp130 interaction reduced pressure-overload-induced cardiac inflammation, remodeling and dysfunction [
27]. Thus, signaling downstream of
IL6 without acute insult to cardiomyocytes can be a detrimental feature that facilitates changes in the myocardium, leading from a physiological to a pathological state.
Although the individual roles of excessive β-adrenergic and
IL6 stimulation in the pathogenesis of cardiomyocyte hypertrophy are well documented, their crosstalk in cardiomyocytes remains controversial. Szabo-Fresnais et al. [
28] observed an enhancement of
IL6 production when ISO was applied to adult ventricular myocytes. Similarly, chronic β-adrenergic stimulation induced myocardial proinflammatory cytokine—including IL6—expression, according to Murray et al. [
29]. In our study, however, acute β-adrenergic stimulation attenuated a tachypacing-induced increase in
IL6 expression (
Figure 3). These seemingly opposing results may be a consequence of the absence (in the study by Szabo-Fresnais et al.) or presence (in our study) of high-pacing-frequency electrical stimulation of cardiomyocytes, which may be critical for qualitative features of β-adrenergic stimulation-driven effects. Murray et al. applied chronic ISO stress via miniosmotic pumps implanted in rats for 7 days; however, they did not assess the potential downregulation or desensitization of β-adrenergic signaling that typically occurs in cardiomyocytes upon upregulation of the β-adrenergic tone. Therefore, it is not possible to assess whether
IL6 overexpression occurs as a result of increased or blunted β-adrenergic response in their study [
29]. In agreement with our data, while ISO was capable of inducing an increase in
IL6 levels in cardiac fibroblasts, it did not cause such response in cultured cardiomyocytes [
30]. Furthermore, it has been recently shown that ISO inhibits transcription of cardiac cytokine genes—including IL6—induced by reactive oxygen intermediates [
31], in a similar fashion to its prevention of
IL6 upregulation due to tachycardia. In addition, as effects of β-adrenergic signaling appear to be highly time-dependent, one has to pay close attention to differential outcomes upon acute vs. chronic β-adrenergic stimulation.
An intriguing aspect of our previous results is that CaMKII inhibition under conditions of tachypacing strongly promoted cardiomyocyte hypertrophy and the expression of NPPB and
IL6 [
9]. We therefore assessed the effect of β-adrenergic stimulation on CaMKII activation upon tachypacing and discovered that—unlike tachycardia alone, which mostly activates CaMKII in the nucleoplasm—ISO treatment potentiates CaMKII activation specifically on the intracellular Ca
2+ stores, while it has no effect on nucleoplasmic CaMKII activation (
Figure 2). This specific spatial activation pattern of CaMKII may be an adaptive mechanism and may keep
IL6 expression low upon acute increase in workload, likely due to the enhanced sarcoplasmic reticulum and nuclear envelope Ca
2+ uptake that prevents nuclear Ca
2+ overload [
9]. In line with this idea, a study by Baier et al. [
32] showed that excessive CaMKII inactivation in AC3-I (autocamtide-3-derived inhibitory peptide) transgenic mice leads to diminished cardiac function and premature death in the first days after inducing pressure overload, highlighting CaMKII activation as an essential element of cardiac stress physiology.
When we initially studied the effects of tachycardia on cardiomyocyte gene reprograming, we found that high pacing frequency alone increases CaMKII activation without an evident accumulation of CaMKII on the nuclear envelope, while nucleoplasmic activation was evident [
5]. Using pharmacological inhibitors of various Ca
2+-regulating proteins, we could also show that this effect occurs downstream of NCX. Although acute application of β-adrenergic stimulating agents has no immediate effect on NCX current in intact rabbit, guinea pig, mouse, and rat ventricular myocytes at low pacing frequencies [
33,
34], 72 h of in vivo β-adrenergic treatment induced an increase in NCX expression [
35]. Strikingly, no cellular or in vivo data are available for the effects of β-adrenergic stimulation in tachycardic conditions. In our experiments, short-term ISO treatment partially prevented tachypacing-induced NCX upregulation, while the addition of ISO + BB completely reversed the effect, thereby highlighting the importance of including (tachy)pacing in the experimental protocol when interpreting data on the effect of β-adrenergic stimulation on physiological stress. On the other hand, numerous studies involving in vivo tachypacing procedure are available, and they readily support our finding that intact β-adrenergic receptor signaling is needed to maintain proper NCX activity under cardiac stress. For example, Briston et al. showed that 5 weeks of in vivo right ventricular tachypacing leads to dysfunctional β-adrenergic receptor signaling with reduced cardiomyocytes responsiveness to β-adrenergic receptor agonists, which is paralleled by greater NCX activity and protein expression [
36]. Although beyond the scope of the current study, measurements of NCX current and activity (e.g., by an altered relaxation of the caffeine-induced Ca
2+ transient) are needed to address the acute functional consequences of rapid-pacing-induced NCX upregulation and the potency of β-adrenergic stimulation in preventing this effect under short-term physiological stress.
Our working hypothesis, based on cellular experiments and qPCR data, is the following (
Figure 6): In a healthy cardiomyocyte, tachypacing induces nuclear CaMKII activation and NCX and
IL6R upregulation. Unlike
IL6R upregulation, it is less likely that altered transcription is the main cause of NCX upregulation—as its mRNA levels remained stable under our experimental conditions ([
5] and
Figure 5A)—but rather increased trafficking and/or decreased degradation. In the presence of β-adrenergic stimulation, however, CaMKII activation is selectively potentiated on intracellular Ca
2+ stores, while NCX and
IL6 upregulation are prevented. Both downstream effects of β-adrenergic stimulation (i.e., CaMKII activation on the nuclear envelope and inhibition of excessive NCX upregulation) are needed to prevent IL6-signaling overactivation upon short-term increase in workload (
Figure 1,
Figure 2 and
Figure 3).
Short-term β-adrenergic receptor stimulation appears essential in preventing inflammatory response during acute stress, which may appear counterintuitive due to the well-documented advantages of BB in treating heart failure. However, in chronic settings, BB treatment prevents the downregulation and/or desensitization of β-adrenergic receptors [
2] and thereby maintains—at least partial—functionality of the receptors. This is likely to maintain cardiomyocytes’ responsiveness to catecholamines (and thus exercise tolerance), but it can also contribute to controlling their inflammatory signaling.
Although chronic β-adrenergic tone is readily implicated in the development of cardiac pathologies, while acute effects are known for instantaneous regulation of cellular Ca
2+ cycling and contractility, little is known about the role of β-adrenergic signaling in preventing gene reprograming under short-term physiological stress. We previously showed that ISO keeps histone deacetylase 4 (HDAC4) localized in the nucleus in the very early response to physiological challenge [
37]. Maccari et al. showed that β-adrenergic signaling also prevents the upregulation of β-myosin heavy chain (β-MHC), and both effects are associated with preventing cardiac dysfunction [
37,
38]. Our present data identify a novel β-adrenergic-signaling-dependent mechanism for controlling transcriptional reprograming during short-term increase in workload demands of the heart. Functional integrity of this cellular mechanism is a prerequisite for keeping
IL6R signaling low and preventing inflammatory response during physiological stress.
To tackle the question of clinical relevance of this newly discovered signaling cascade downstream to β-adrenergic receptor, we studied
Dahl salt-sensitive rats fed high-salt diet for 10 weeks. Upon being treated with our feeding protocol (
Figure S1A), these rats developed severe hypertension, diastolic dysfunction and cardiac hypertrophy on an organ and cardiomyocyte level (
Figure S1), and most importantly for this study, they showed depressed β-adrenergic signaling (
Figure 4), which is typically observed in cardiac pathologies in the clinical setting [
39,
40]. We showed that reduced β-adrenergic signaling was associated with strong NCX upregulation and that enhancement of
IL6R-signaling was one of the most affected pathways in microarray analyses (
Figure 5). According to our cellular data, such loss in β-adrenergic responsiveness would upregulate NCX under tachycardic pacing stress, an effect likely potentiated by the mechanical stress to individual myocytes caused by hypertension [
5], thus together leading to
IL6R upregulation. From our data, we cannot completely rule out the involvement of other pathways with downstream effects on
IL6R in two etiologically distinct models used in the study. However, observed changes in
NRVCMs are completely recapitulated in the adult
Dahl salt-sensitive rats, arguing for at least partial activation of the same signaling pathway in both models and the more universal role of β-adrenergic receptor signaling in preventing inflammatory overactivation. In line with this, adverse diastolic phenotype—similar to that observed in our hypertensive rat model—was previously associated with enhanced
IL6 signaling. For example, the BIOSTAT-CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure) trial data demonstrated that suffering from heart failure with preserved ejection fraction (HFpEF) was a strong independent predictor of increased
IL6 levels [
41], while the PREVEND (Prevention of Renal and Vascular End-Stage Disease) study found
IL6 levels significantly associated with the development of HFpEF but not heart failure with reduced ejection fraction (HFrEF) [
42]. Our data support the need for further research to investigate whether
IL6 might be a potential novel treatment target to halt or even prevent HFpEF.
One important point of consideration is the origin of
IL6 and
IL6R in myocardial tissue of hypertensive
Dahl salt-sensitive rats detected in microarray analyses, as
IL6 can be secreted by both human cardiomyocytes and cardiac fibroblasts [
43]. A recent study by Kumar et al., however, showed that
IL6 expression in cardiac fibroblasts cannot be stimulated by transverse aortic constriction or exposure to pro-hypertrophic factors, including phenylephrine, angiotensin II, transforming growth factor-β, and hypoxia. In contrast, conditioned medium from cardiomyocytes with increased
IL6 production due to hypoxia-induced mitogenic factor (HIMF) can increase
IL6 production in fibroblasts and their proliferation, migration, and myofibroblast differentiation [
26]. These data support that
IL6 signaling in cardiac fibrosis is activated via a cardiomyocyte-to-fibroblast paracrine effect, with
IL6 signaling in cardiomyocytes playing a central role in cardiomyocyte hypertrophy.
In summary, we have demonstrated that β-adrenergic stimulation has a direct effect on NCX protein expression and downstream CaMKII subcellular activation/localization upon increased workload of the heart, which prevents augmentation of IL6R signaling. We propose a previously unidentified protective role of short-term ISO stimulation in inhibiting IL6R activation and NCX dysregulation. A better understanding of these processes may contribute to refinement of existing therapeutic options for patients with compromised β-adrenergic signaling.